[1]
C.-W. Park, C.-T. Han, Y. Sakaguchi, J. Lee, and H.-Y. Youn, “The safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis”, EXCLI J., vol. 19, pp. 187–200, Feb. 2020.